MabSpace Biosciences Co. Ltd logo

MabSpace Biosciences Co. Ltd

MabSpace Biosciences Co., Ltd. specializes in the discovery and early-development of antibody-based therapeutics, with a focus on developing best-in-class and first-in-class antibody therapeutics for cancer treatment.

MabSpace is headquartered in Hong Kong and has an R&D subsidiary with fully-integrated in vitro and in vivo pharmacology profiling capabilities in Biobay, Suzhou Industrial Park.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.mabspacebio.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
218 Xinghu Street, Biobay B2-609,215123
Suzhou
China
Email
Contact Number
+86 512-86861701

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

MabSpace proprietary immune tolerance breaking technology (IMTB) enables the development of antibodies targeting diverse epitope space on a given target, including those epitopes with high degree of cross-species identity in amino acid.

In May 2015, MabSpace signed a collaboration contract with Jiangsu Hengrui Medicine. Under the terms, MabSpace will be responsible for the discovery and selection of humanized lead antibodies, while Hengrui will get exclusive global rights on the resulting therapeutic candidates, and will further develop the selected candidate molecules. Financial details were undisclosed.

In May 2015, MabSpace Biosciences signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China. Under the terms, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio to further develope them and will own exclusive global rights on the resulting therapeutic candidates, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales. The exact financial details were undisclosed.

In Oct 2015, MabSpace Biosciences raised $15 Mn in Series A financing form Lilly Asia Ventures.